Loading
A phase 2 trial of F182112, Pomalidomide in multiple myeloma, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07312188 by Shandong New Time Pharmaceutical Co., LTD, with 90 participants planned, started 2025-07-02 and due to reach its primary completion in 2028-05-20. Interventions recorded: F182112+P, F182112+CD38. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares F182112, Shandong New Time Pharmaceutical, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Pomalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/